Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger(University of Chicago), Thomas F. Gajewski(University of Chicago)
Cited by 652
Related Papers
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
|Journal for ImmunoTherapy of Cancer|2014|543
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
|Journal of Clinical Oncology|2018|382
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
|Journal for ImmunoTherapy of Cancer|2019|157